Evidence map›Paper›PMID 25859007›Full record

ArticleHuman molecular genetics2015

CEP290 alleles in mice disrupt tissue-specific cilia biogenesis and recapitulate features of syndromic ciliopathies.

Rivka A Rachel, Erin A Yamamoto, Mrinal K Dewanjee, Helen L May-Simera, Yuri V Sergeev, Alice N Hackett, Katherine Pohida, Jeeva Munasinghe, Norimoto Gotoh, Bill Wickstead and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Human molecular genetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers.

0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed
8.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

83 citing papers in PubMed, 126 citations in OpenAlex.

  1. Trial
  2. Review
  3. The kinesin-4 protein KIF27 forms a cytoskeletal scaffold at the transition zone to promote motile cilia structural integrity.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Genetic mutation ofLife science alliance · 2024
    Article
  15. Formation and function of multiciliated cells.The Journal of cell biology · 2024
    Review
  16. Cell-cell interaction in the pathogenesis of inherited retinal diseases.Frontiers in cell and developmental biology · 2024
    Review
  17. Article
  18. Clinical and Molecular Aspects of C2orf71/PCARE in Retinal Diseases.International journal of molecular sciences · 2023
    Review
  19. Article
  20. Kinase Inhibitors in Genetic Diseases.International journal of molecular sciences · 2023
    Review

23 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Rivka A RachelNational Eye Institute.
Erin A YamamotoNational Eye Institute.
Mrinal K DewanjeeNational Eye Institute.
Helen L May-SimeraNational Eye Institute.
Yuri V SergeevNational Eye Institute.
Alice N HackettNational Eye Institute.
Katherine PohidaNational Eye Institute.
Jeeva MunasingheNational Institute of Neurological Disease and Stroke, National Institutes of Health, Bethesda, MD 20892, USA and.
Norimoto GotohNational Eye Institute.
Bill WicksteadSchool of Life Sciences, University of Nottingham, Nottingham, UK.
Robert N FarissNational Eye Institute.
Lijin DongNational Eye Institute.
Tiansen LiNational Eye Institute.
Anand SwaroopNational Eye Institute, swaroopa@nei.nih.gov.
National Eye Institute · USNational Institutes of Health · USUniversity of Nottingham · GB

Funding

Mechanisms, modeling and therapies of retinal and macular neurodegenerationZIAEY000546 · NEI · NATIONAL EYE INSTITUTE · PI SWAROOP, ANAND · 2015 to 2025
$36.3M
Disease mechanism and therapies for retinal degenerationZIAEY000490 · NEI · NATIONAL EYE INSTITUTE · PI LI, TIANSEN · 2010 to 2025
$30.4M
NEI Genetic Engineering CoreZICEY000458 · NEI · NATIONAL EYE INSTITUTE · PI DONG, LIJIN · 2009 to 2025
$22.6M
Proteins From Hereditary Eye Diseases: In-silico and Experimental StudiesZIAEY000476 · NEI · NATIONAL EYE INSTITUTE · PI SERGEEV, YURI · 2009 to 2025
$16.8M
Imaging Core UnitZICEY000459 · NEI · NATIONAL EYE INSTITUTE · PI FARISS, ROBERT · 2009 to 2025
$13.1M
6 · The paper itself

Abstract

Distinct mutations in the centrosomal-cilia protein CEP290 lead to diverse clinical findings in syndromic ciliopathies. We show that CEP290 localizes to the transition zone in ciliated cells, precisely to the region of Y-linkers between central microtubules and plasma membrane. To create models of CEP290-associated ciliopathy syndromes, we generated Cep290(ko/ko) and Cep290(gt/gt) mice that produce no or a truncated CEP290 protein, respectively. Cep290(ko/ko) mice exhibit early vision loss and die from hydrocephalus. Retinal photoreceptors in Cep290(ko/ko) mice lack connecting cilia, and ciliated ventricular ependyma fails to mature. The minority of Cep290(ko/ko) mice that escape hydrocephalus demonstrate progressive kidney pathology. Cep290(gt/gt) mice die at mid-gestation, and the occasional Cep290(gt/gt) mouse that survives shows hydrocephalus and severely cystic kidneys. Partial loss of CEP290-interacting ciliopathy protein MKKS mitigates lethality and renal pathology in Cep290(gt/gt) mice. Our studies demonstrate domain-specific functions of CEP290 and provide novel therapeutic paradigms for ciliopathies.

Indexed as

AnimalsAntigens, NeoplasmCell Cycle ProteinsCiliaCytoskeletal ProteinsDisease Models, AnimalFemaleHumansHydrocephalusKidney Diseases, CysticMaleMiceMice, Inbred C57BLMice, KnockoutNuclear ProteinsOrgan SpecificityAntigens, NeoplasmCell Cycle ProteinsCep290 protein, mouseCytoskeletal ProteinsNuclear Proteins

Identifiers

PMID25859007
PMCPMC4459394
OpenAlexW2114070420

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.